Actively Recruiting
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Led by University of California, Los Angeles · Updated on 2025-05-11
20
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.
CONDITIONS
Official Title
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
- Age over 18 years
- Male or post-menopausal female
You will not qualify if you...
- History of prior neck surgery and/or neck irradiation
- Use of beta blocker agents
- Use of any other glucose lowering medication
- History of neuropathic disorders (e.g. diabetic neuropathy)
- Diabetic patients
- Individuals without normal thyroid function
- Individuals with cancer
- Any significant chronic disease or renal, hepatic or endocrine disease
- Current smokers
- Inability to provide consent due to medical or psychiatric reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UCLA Health
Los Angeles, California, United States, 90095
Actively Recruiting
Research Team
P
Preethi Srikanthan, MD
CONTACT
J
Julie Sorg, MSN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here